Mechanism by which metformin inhibits food intake

November 03, 2013

Metformin may reduce food intake and body weight, but the anorexigenic effects of metformin are still poorly understood. Under normal physiological conditions, Prof. Zheng Zhao and his team from the Key Laboratory of Brain Functional Genomics, Ministry of Education, China observed the changes in food intake after administration of metformin. They found that the central administration of metformin significantly reduced food intake and body weight gain, and a reduction of neuropeptide Y expression and induction of AMP-activated protein kinase phosphorylation in the hypothalamus were also observed, which could be reversed by compound C, a commonly-used antagonist of AMP-activated protein kinase. Furthermore, metformin also improved lipid metabolism by reducing plasma low-density lipoprotein. These findings were published in the Neural Regeneration Research (Vol. 8, No. 25, 2013).
-end-
Article: " Metformin inhibits food intake and neuropeptide Y gene expression in the hypothalamus " by Yale Duan1, Rui Zhang1, Min Zhang2, Lijuan Sun1, Suzhen Dong1, Gang Wang2, Jun Zhang2, Zheng Zhao1 (1 Key Laboratory of Brain Functional Genomics, Ministry of Education, Shanghai Key Laboratory of Brain Functional Genomics, East China Normal University, Shanghai 200062, China; 2 Department of Clinical Laboratory, Shanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China)

Duan YL, Zhang R, Zhang M, Sun LJ, Dong SZ, Wang G, Zhang J, Zhao Z. Metformin inhibits food intake and neuropeptide Y gene expression in the hypothalamus. Neural Regen Res. 2013;8(25):2379-2388.

Contact: Meng Zhao
eic@nrren.org
86-138-049-98773
Neural Regeneration Research
http://www.nrronline.org/

Full text: http://www.sjzsyj.org/CN/article/downloadArticleFile.do?attachType=PDF&id=711

Neural Regeneration Research

Related Metformin Articles from Brightsurf:

A molecule from gut bacteria reduces effect of diabetes medication
The action of metformin, the classic drug used to treat diabetes by stabilizing blood sugar, can be blocked by a molecule from the bacteria in our intestines, a University of Gothenburg study shows.

Metformin treatment linked to slowed cognitive decline
A six-year study of older Australians with type 2 diabetes has uncovered a link between metformin use, slower cognitive decline and lower dementia rates.

Metformin for type 2 diabetes patients or not? Researchers now have the answer
Metformin is the first-line drug that can lower blood sugar levels in type 2 diabetes patients.

An exploratory study of metformin and rapamycin as maintenance therapy
Volume 11, Number 21 of @Oncotarget reported that eligible patients with stable or responding mPDA after 6 months on chemotherapy were randomized 1:1 to metformin alone or with rapamycin, stratified by prior treatment with FOLFIRINOX.

Examining association of preoperative metformin, surgical outcomes in patients with diabetes
Metformin is the most commonly prescribed noninsulin medication for type 2 diabetes and this observational study examined postoperative death and hospital readmission among adults with type 2 diabetes who had a prescription for metformin before major surgery with those who didn't.

Can metformin reduce obesity in children and adolescents?
A new study has shown metformin -- a glucose-lowering drug commonly used to treat diabetes -- to be effective at lowering some measures of obesity in children and adolescents.

Secret behind diabetes drug's benefits revealed
Researchers went into this study with the idea that metformin might communicate with other tissues in the body by causing the secretion of a protein from the liver.

Study shows metformin offers no strength training benefits for seniors
A clinical trial initiated by University of Kentucky researchers argues against the hypothesis that the diabetes drug metformin could help exercising seniors gain more muscle mass.

Diabetes drug study explores cardiovascular risks for patients with kidney disease
Among the 30 million U.S. adults with Type 2 diabetes, 20% have impaired kidney function.

LSU Health research targets metformin as breast cancer prescription
Research conducted by Suresh Alahari, PhD, Professor of Biochemistry and Genetics at LSU Health New Orleans School of Medicine, has found that metformin, a commonly prescribed drug for Type 2 Diabetes, may be effective in treating cancers that lack a protein called Nischarin.

Read More: Metformin News and Metformin Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.